成都治疗下肢静脉曲张用多少钱成都婴儿血管瘤专科,成都血管畸形哪里好治,成都治疗海绵状血管瘤价格,成都有脉管炎如何治疗,成都治腿静脉曲张手术多少钱,成都下肢动脉硬化初期治疗,成都哪个血糖足医院比较好

WASHINGTON, Jan. 2 (Xinhua) -- A hormone derived from visceral fat called adiponectin may play a role as a risk factor for development of all-cause dementia and Alzheimer's disease (AD) in women, according to a study published on Monday in online issue of the Archives of Neurology.Thomas van Himbergen, from Human Nutrition Research Center on Aging at Tufts University, and colleagues measured levels of glucose, insulin, and glycated albumin, as well as C reactive protein, lipoprotein associated phospholipase A2, and adiponectin in the plasma of patients at the 19th biennial examination (1985 -- 1988) of the Framingham Heart Study.The 840 patients (541 women, median age of 76 years) were followed-up for an average of 13 years and evaluated for signs of the development of AD and all-cause dementia. During that time, 159 patients developed dementia, including 125 cases of AD. After adjustment for other dementia risk factors (age, low plasma docosahexaenoic acid, weight change) only adiponectin in women was associated with an increased risk of all-cause dementia and AD."It is well established that insulin signaling is dysfunctional in the brains of patients with AD, and since adiponectin enhances insulin sensitivity, one would also expect beneficial actions protecting against cognitive decline," the authors write. "Our data, however, indicate that elevated adiponectin level was associated with an increased risk of dementia and AD in women."

BEIJING, Jan. 7 (Xinhua) -- The two-day National Financial Work Conference concluded Saturday, laying out development plans for the financial sector in the coming five years, according to a statement released after the meeting.Chinese Premier Wen Jiabao was present at the conference and delivered a keynote speech.Such a conference is held every five years. Similar meetings were held in 1997, 2002 and 2007.

SAN FRANCISCO, Oct. 10 (Xinhua) -- Apple announced on Monday that pre-orders of its iPhone 4S have topped 1 million in a single day, surpassing the previous single-day pre-order record of the company's smartphone.The iPhone 4S pre-orders surpassed 1 million in the first 24 hours and the previous single day pre-order record held by iPhone 4 is 600,000, according to Apple."We are blown away with the incredible customer response to iPhone 4S," Philip Schiller, Apple's senior vice president of worldwide product marketing, said in a statement."The first day pre-orders for iPhone 4S have been the most for any new product that Apple has ever launched and we are thrilled that customers love iPhone 4S as much as we do," he added.U.S., newly installed Chief Executive Officer Tim Cook takes stage to give a general introduction of Apple's products, Oct. 4, 2011. Apple Inc. last Tuesday unveils iPhone 4S, the much-anticipated latest generation of iPhone.The iPhone 4S, which looks the same as the iPhone 4 but has major hardware upgrade inside, is available for pre-order last Friday and set to first arrive in stores in the United States this Friday.So far, iPhone 4, which, according to Apple, has been sold more than the first three generations of iPhones combined, is Apple's best selling iPhone.The pre-order numbers are good news for Apple as the initial introduction of iPhone 4S last Tuesday has not lived up to the anticipation of some investors and analysts, and spurred a new wave of concerns about whether the company could keep its innovation momentum in the wake of the passing of its co-founder Steve Jobs last Wednesday.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.

XI'AN, Nov. 20 (Xinhua) -- Fish in Hongjiannao Lake, China's largest desert freshwater lake, are teetering on the verge of extinction, according to local fishery authorities."The fish in Hongjiannao have nearly vanished," said Li Weiping, the head of a fish monitoring station in northwest China's Shaanxi province.As the lake continues to shrink, its water has become more salty and its pH reading has reached 9.6, while the maximum reading suitable for fish is 8.5, according to Li.The lake has gradually lost the water that it used to get from underground streams and rivers, Li said, adding that excessive coal mining around the lake has changed the way water flows underground. Two reservoirs have been built on two rivers near the upper reaches of the lake, preventing river water from flowing into the lake.The lake's water level has plunged by 20 to 30 centimeters every year. Its total surface area has been reduced to 41.8 square km, down from 67 km in 1996.